Company Vivoryon Therapeutics AG Euronext Amsterdam
Equities
DE0007921835
Biotechnology & Medical Research
Business Summary
At the end of 2022, the group has a portfolio of a product in phase II clinical development (Varoglutamstat; PQ912) and 2 products in the preclinical development phase.
Managers
Managers | Title | Age | Since |
---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 11-12-31 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Director/Board Member | 56 | 18-08-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 74 | 06-12-31 | |
Director/Board Member | 54 | 06-12-31 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Samir Shah
BRD | Director/Board Member | 63 | 21-12-31 |
Director/Board Member | 56 | 18-08-30 | |
Frank Weber
CEO | Chief Executive Officer | 64 | 11-12-31 |
Claudia Riedl
BRD | Director/Board Member | 54 | 21-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 25,961,892 | 17,348,972 ( 66.82 %) | 0 | 66.82 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+47.58% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
+27.16% | 12.05B | |
-3.63% | 11.7B | |
+7.30% | 11.1B |